Global Growth Opportunities Capitalize on Caris' multi-office presence and distributor network to scale comprehensive molecular profiling and AI-driven decision support across major US and international cancer centers, IDNs, and research partners. The integrated platform offering whole exome and whole transcriptome sequencing with clinico-genomic analytics can drive higher test volumes, recurring revenue, and data partnerships.

Precision Diagnostics Market the Caris MI Clarity prognostic test for postmenopausal patients with HR-positive/HER2-negative early-stage breast cancer to breast and oncology centers, enabling at-diagnosis risk stratification for distant recurrence and guiding adjuvant therapy decisions.

Pharma Collaboration Leverage the clinico-genomic database and AI capabilities to support biomarker-driven drug development and companion diagnostics. Partner with pharma and biotech sponsors to improve patient stratification, accelerate trial enrollment, and tailor therapy selection using validated molecular signatures, including glioblastoma predictors.

Academic Partnerships Expand collaborations with leading cancer centers and academic institutions, building on ongoing alliances such as UCSF’s Precision Oncology Alliance. Position Caris as a partner for research collaborations, clinical trials, and data analytics platforms to advance precision oncology in real-world settings.

Disease Focus Expansion Build on current focus areas in breast cancer and glioblastoma to broaden coverage across additional tumor types with AI-guided profiling and monitoring capabilities, offering scalable services to hospitals and providers seeking precision medicine solutions and data-driven treatment pathways.